Clinical Study Results
What adverse reactions did the participants have?
The most common adverse reaction was diarrhea.
The adverse reactions in the table below happened in 10.0% or more of the participants
overall. There were other adverse reactions, but those happened in fewer participants.
Most common adverse reactions during the study
Part A 200 mg Part A 175 mg Part B 175 mg
AZD1775 AZD1775 AZD1775 Total
(out of 7 (out of 5 (out of 80 (out of 92
participants) participants) participants) participants)
Diarrhea 85.7% (6) 40.0% (2) 56.3% (45) 57.6% (53)
Nausea 100.0% (7) 40.0% (2) 42.5% (34) 46.7% (43)
Tiredness 71.4% (5) 40.0% (2) 36.3% (29) 39.1% (36)
Vomiting 85.7% (6) 60.0% (3) 18.8% (15) 26.1% (24)
Decreased appetite 28.6% (2) 20.0% (1) 12.5% (10) 14.1% (13)
How has this study helped patients and researchers?
This study helped researchers learn more about how AZD1775 works in patients with
advanced solid tumors, and what AZD1775 dose is safest to take.
Researchers look at the results of many studies to decide which treatments work best
and are safest. This summary shows only the main results from this one study. Other
studies may provide new information or different results.
Other clinical studies with AZD1775 are ongoing at the time of the writing of this
document.
11